Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Noteableon Feb 06, 2023 8:02pm
898 Views
Post# 35270702

USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China
December 2022 - "The White House and Congress are quietly reshaping the American economic relationship with the world’s second-largest economic power, enacting a strategy to limit China’s technological development that breaks with decades of federal policy and represents the most aggressive American action yet to curtail Beijing’s economic and military rise."

The new strategy, which the Biden administration internally calls its “protect agenda,” is being rolled out this fall and winter in a series of executive actions. In October, the Commerce Department issued new rules aimed at cutting off Chinese firms’ ability to manufacture advanced computer chips. They will soon be followed by an executive order creating new federal authority to regulate U.S. investments in China — the first time the federal government will exert such power over American industry – and an executive order to limit the ability of Chinese apps like TikTok to collect data from Americans. 

In particular, Sullivan has highlighted biotechnology and clean energy as two industries where the U.S. must not let China take the lead. But White House policymakers say those actions will be “carefully tailored” to affect only high-end, strategic products, and not cut off everyday commerce.  


“Clean tech, biotechnology — these are sectors that are poised for significant growth,” said a senior administration official, who spoke anonymously to detail administration policies. 

The new initiatives to curtail Chinese tech firms represent a shift from the optimistic stance toward technological development that defined American policy for decades. 

Throughout the end of the Obama administration and through Trump’s term, national security officials struggled to convince their colleagues in other agencies that commercial interests in the Chinese economy should, at least, be tempered by security considerations. 

In his September speech, Sullivan outlined three broad sectors where the administration would try to stall Chinese development: computing (including chips, quantum computing and artificial intelligence), biotechnology and biomanufacturing, and clean energy tech.

The U.S. government moves beyond the semiconductor sectors and seeks to stall or outpace China’s development in other critical sectors like biotech and clean energy


https://www.politico.com/news/2022/12/26/china-trade-tech-00072232

<< Previous
Bullboard Posts
Next >>